Comparative Pharmacology
Head-to-head clinical analysis: DELFLEX LM W DEXTROSE 3 5 IN PLASTIC CONTAINER versus INPERSOL LC LM W DEXTROSE 3 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DELFLEX LM W DEXTROSE 3 5 IN PLASTIC CONTAINER versus INPERSOL LC LM W DEXTROSE 3 5 IN PLASTIC CONTAINER.
DELFLEX-LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER vs INPERSOL-LC/LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DELFLEX-LM W/ DEXTROSE 3.5% is a peritoneal dialysis solution. Its mechanism of action involves osmotic ultrafiltration across the peritoneal membrane, facilitated by high dextrose concentration, to remove excess fluid and waste products (e.g., urea, creatinine) from the blood in patients with end-stage renal disease.
Inpersol-LC/LM with 3.5% dextrose is a peritoneal dialysis solution that provides osmotic ultrafiltration via dextrose, removing waste products and excess fluid from the blood across the peritoneal membrane. The low calcium (LC) and low magnesium (LM) formulations adjust electrolyte concentrations to manage imbalances.
Intraperitoneal: 1.5% to 4.25% dextrose solution; 2 to 2.5 L per exchange, typically 4 exchanges per 24 hours; dwell time 4 to 6 hours.
Intraperitoneal administration: 2 to 2.5 liters per exchange, 4 to 5 exchanges per day, as prescribed by physician based on peritoneal equilibration test.
None Documented
None Documented
Not applicable for dextrose; for lactate/bicarbonate buffer components, half-life is approximately 2-4 hours in peritoneal cavity with systemic absorption minimal. Clinical context: continuous dialysis maintains steady-state.
Not applicable; dextrose is continuously infused and removed; the half-life of intraperitoneal dextrose is approximately 1-2 hours due to rapid absorption and metabolism, with clinically relevant hyperglycemia managed by insulin.
Peritoneal dialysis: Removal of waste products (urea, creatinine) via peritoneal membrane; approximately 60-80% of urea is removed during a 4-6 hour dwell. Biliary/fecal: minimal (<5%). Renal: negligible as drug is primarily used in renal failure.
Renal (via peritoneal dialysis effluent); approximately 60-70% of administered dextrose is absorbed and metabolized, with the remainder removed in dialysate; no significant biliary/fecal elimination.
Category C
Category C
Peritoneal Dialysis Solution
Peritoneal Dialysis Solution